
🧬 Eli Lilly Eyes $2B+ Kelonia Deal — Here’s Why the Math Makes Sense
Lilly doesn’t need Kelonia to survive. It needs it to dominate
Read More: https://bit.ly/Buy-LLY
#EliLilly #LLY #Oncology #CART #Biotech #MultipleMyeloma #PharmaMandA #InvestorInsight #Hematology #HealthcareInvesting #BioPharma #GrowthStrategy
